Safe Biologics

DECEMBER 3, 2023

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Safe Biologics

JANUARY 12, 2024

The automatic substitution of biosimilars is a controversial practice, banned in many countries including nearly all of Western Europe. Oregon state law currently only permits biosimilars that the FDA has approved as interchangeable to be automatically substituted.

Biosimilars 130

Biosimilars Drug Pricing 130

STAT

MARCH 3, 2023

… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. And the Mark Cuban Cost Plus Drug Co. But drug=pricing experts predict Lilly’s moves will not undercut those efforts.

Drug Pricing 210

Drug Pricing Biosimilars 210

Safe Biologics

OCTOBER 10, 2023

ASBM Statement on Announcement of Medicare Drug Price-Setting List On August 29th, the Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs selected under its Medicare drug price “negotiation” plan, authorized by the Inflation Reduction Act (IRA) signed into law last year.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

FDA Law Blog: Biosimilars

SEPTEMBER 15, 2024

To that end, we were recently alerted to the fact that the Senate Committee on the Judiciary has scheduled an Executive Business Meeting for Thursday, September 19, 2024 to mark-up, among other things, two bills of interest: (1) S. But as AAM notes in a March 2024 letter opposing S. Reading through the “Findings” section of S.

Biosimilars 74

Biosimilars Drug Pricing 74

Drug Channels

JULY 23, 2024

These data remain inconvenient for drug pricing flat earthers (#DPFE): When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2023. Insulin has been the first to deflate—and the Humira biosimilar market may be next. You can find links to each company’s data below.

Drug Pricing 52

Drug Pricing Pharmaceutical Manufacturing Biosimilars 52

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Drug Pricing 84

Drug Pricing Biosimilars 84

Big Molecule Watch

AUGUST 25, 2023

The Inflation Reduction Act’s Medicare Drug Price Negotiation Program will kick off next week. There are reports that the White House may announce the list of selected drugs even before that deadline, on Tuesday, August 29 th. Before the IRA, the government could not set prices for any drugs covered by Medicare.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

Safe Biologics

DECEMBER 6, 2023

prescribers have high confidence in the safety and efficacy of biosimilars, a majority (58%) oppose third-party switching of a patient’s biologic medicine for non-medical (e.g. state law, only biosimilars which are interchangeable may be substituted by a pharmacist without contacting the prescriber. and worldwide.”

Biosimilars 130

Biosimilars Packaging Labelling Drug Development 130

FDA Law Blog: Biosimilars

JUNE 16, 2023

Kirschenbaum — On May 24, Minnesota enacted the Commerce and Consumer Protection Omnibus Bill, Senate File 2744 ( SF 2744 ), which significantly expands the state’s existing drug pricing activities with serious implications for all drug manufacturers, and particularly generic drug manufacturers.

Drug Pricing 44

Drug Pricing Biosimilars Dosage Documentation 44

Drug Channels

OCTOBER 7, 2024

What are the most effective strategies for spread pricing and reimbursement models? What is the best solution to navigate the challenges of the 340B drug pricing program and PBM contracting? What market dynamics and barriers are impacting pricing and demand? How can I ensure compliance with ERISA requirements?

Drug Pricing 73

Drug Pricing Biosimilars 73

Big Molecule Watch

JANUARY 25, 2024

As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023. The approval of Amgen’s WEZLANA (ustekinumab-auub) as biosimilar to Janssen’s STELARA (ustekinumab) is noteworthy given that it received designation as interchangeable.

Biosimilars 57

Biosimilars Labelling Drug Pricing 57

Big Molecule Watch

MARCH 1, 2024

Today, the district court for the District of Delaware (Judge Connolly) granted the government’s motion for summary judgment on all claims brought by AstraZeneca in its Complaint challenging the Drug Price Negotiation Program of the IRA. There are now seven remaining lawsuits challenging the Drug Price Negotiation Program of the IRA.

Biosimilars 57

Biosimilars Drug Pricing Dosage Documentation 57

FDA Law Blog: Biosimilars

AUGUST 14, 2024

In addition to the widely publicized drug price negotiation program, the IRA established inflation rebate programs under Medicare Part B and Part D. On July 31, 2024, CMS published a proposed rule to codify its guidances, with some changes.

Drug Pricing 57

Drug Pricing Pharmaceutical Manufacturing 57

Big Molecule Watch

JANUARY 19, 2024

As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. The following is a recap of some of the top five legal decisions and developments in the biosimilars and biologics space in 2023 that we covered on the Big Molecule Watch.

Biosimilars 73

Biosimilars Dosage Drug Pricing 73

European Pharmaceutical Review

JANUARY 18, 2024

“The dominance of the US within the 7MM is due to its larger insomnia population and higher drug prices. GlobalData considered drug pricing and market exclusivity to be two major obstacles. billion by 2024. billion across the 7MM up to 2032, GlobalData’s predicted in a report published in December 2023.

Drug Pricing 98

Drug Pricing Biosimilars Compounding 98

pharmaphorum

JANUARY 13, 2023

The complaint – which comes as insulin has become the focal point of the drug pricing debate in the US – alleges that Novo Nordisk, Lilly, and Sanofi “aggressively raised the list price of insulin in lockstep with each other.” Some companies are already taking steps to provide lower-cost products.

Diabetes 104

Diabetes Drug Pricing Biosimilars 104

Safe Biologics

MAY 10, 2024

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. and Europe alike, prescribers can already substitute any biosimilar for its reference product. Currently there are 10 biosimilars that can be substituted by U.S.

Biosimilars 130

Biosimilars Drug Pricing Documentation Labelling 130

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

There have already been (with more coming) a slew of 40th anniversary celebration papers, analyses, and events in 2024, including: The Brookings Institution’s Hatch-Waxman at 40 The Association for Accessible Medicines’ Hatch-Waxman turns 40. And that name has stuck for many of us. Is it over the hill? (Or

Dosage 57

Dosage Drug Pricing 57

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year.

Labelling 104

Labelling Drug Pricing Compounding Payment Processing 104

FDA Law Blog: Biosimilars

APRIL 16, 2024

Gaulkin — On April 10, the Fourth Circuit unanimously affirmed a summary judgment ruling for the Centers for Medicare & Medicaid Services (CMS) regarding the agency’s definitions of “line-extension drug” and “new formulation” for purposes of determining rebates that drug manufacturers may owe the Medicaid Drug Rebate Program (MDRP).

Dosage 57

Dosage Drug Pricing Pharmaceutical Manufacturing 57

FDA Law Blog: Biosimilars

MARCH 24, 2024

Under this law, manufacturers may not deny contract pharmacies access to a covered entity’s 340B drugs, or deny 340B drug pricing to covered entities who use contract pharmacies for distribution. On March 12, 2024, a three-judge panel of the Eighth Circuit affirmed. 22-3675, 2024 U.S. 2024) at 13 (“Decision”).

Drug Pricing 57

Drug Pricing 57

FDA Law Blog: Biosimilars

MARCH 5, 2024

By Faraz Siddiqui — Last Friday, the Delaware District Court rejected AstraZeneca’s lawsuit against the Medicare Drug Price Negotiation Program enacted under the Inflation Reduction Act (IRA) and CMS’s guidance implementing it. at least one drug” has been approved and marketed. 16 June 2023) Eliquis Novartis D.N.J. (1

Dosage 62

Dosage Drug Pricing 62

Pharmaceutical Technology

SEPTEMBER 26, 2022

The company told GlobalData PharmSource: “The biosimilar facilities in Austria and Slovenia would continue to manufacture biosimilars for Sandoz under a contractual agreement with Novartis. This came after an attempted sell-off starting last October was met with no formal offers from a buyer. The site employs around 250 people.

Biosimilars 64

Biosimilars Drug Development Vaccines Dosage 64

Pharma in Brief

JANUARY 10, 2024

We also flag what to watch out for in 2024. Expected highlights for 2024 include a final PTA regime, more details on PMPRB drug pricing guidelines and national pharmacare, and fall-out from the US mass drug importation program targeting Canadian medicines. mL formulation in Canada”.

Drug Pricing 52

Drug Pricing Documentation Biosimilars Vaccines 52

pharmaphorum

MARCH 23, 2022

Earlier this month, non-profit drugmaker Civica Rx pledged to launch biosimilars of three big-selling insulin products in the US – Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) – by 2024.

Diabetes 75

Diabetes Biosimilars Drug Pricing 75

STAT

JULY 15, 2024

In April, the lawmakers wrote to the company expressing alarm at its decision, announced in November, that it would permanently discontinue Levemir by the end of 2024.

Drug Pricing 190

Drug Pricing Biosimilars Diabetes 190

pharmaphorum

MAY 13, 2022

Earlier this month, non-profit drugmaker Civica Rx pledged to launch biosimilars of three big-selling insulin products in the US – Sanofi’s Lantus, Novo Nordisk’s Novolog and Eli Lilly’s Humalog – by 2024. Some companies are already taking steps to provide lower-cost products.

Diabetes 59

Diabetes Biosimilars Drug Pricing 59

Drug Channels

NOVEMBER 12, 2024

president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2025 This event will be broadcast live on Friday, December 13, 2024, from 12:00 p.m. This event is part of The Drug Channels 2024 Video Webinar Series.

Drug Pricing 84

Drug Pricing Biosimilars Labelling 84

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Negotiations over these products are expected from October 2023 and run until August 2024. Free Report.

Drug Pricing 64

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 64

Pharmaceutical Technology

JANUARY 16, 2023

The topic of inflation overlaps with drug pricing strategy themes. Policymakers are attempting to respond to inflation crises by introducing new frameworks on the regulation of drug prices. Negotiations over these products are expected from October 2023 and run until August 2024. Free Report.

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52